Intranasal delivery of experimental compounds in orthotopic brain tumor mouse models

Effective therapeutics for malignant primary brain tumors, such as glioblastomas (GBMs), are urgently needed. To facilitate and expedite early-phase GBM therapeutic development, we describe a protocol that allows the intranasal delivery of experimental compounds in GBM orthotopic mouse models. Compo...

Descripción completa

Detalles Bibliográficos
Autores principales: Eyme, Katharina M., Carvalho, Litia, Badr, Christian E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821034/
https://www.ncbi.nlm.nih.gov/pubmed/33532737
http://dx.doi.org/10.1016/j.xpro.2020.100290
_version_ 1783639338717806592
author Eyme, Katharina M.
Carvalho, Litia
Badr, Christian E.
author_facet Eyme, Katharina M.
Carvalho, Litia
Badr, Christian E.
author_sort Eyme, Katharina M.
collection PubMed
description Effective therapeutics for malignant primary brain tumors, such as glioblastomas (GBMs), are urgently needed. To facilitate and expedite early-phase GBM therapeutic development, we describe a protocol that allows the intranasal delivery of experimental compounds in GBM orthotopic mouse models. Compounds delivered through this route can bypass the blood-brain barrier and thus help validate effective therapeutic targets for GBMs. For complete details on the use and execution of this protocol, please refer to Pinkham et al. (2019).
format Online
Article
Text
id pubmed-7821034
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78210342021-02-01 Intranasal delivery of experimental compounds in orthotopic brain tumor mouse models Eyme, Katharina M. Carvalho, Litia Badr, Christian E. STAR Protoc Protocol Effective therapeutics for malignant primary brain tumors, such as glioblastomas (GBMs), are urgently needed. To facilitate and expedite early-phase GBM therapeutic development, we describe a protocol that allows the intranasal delivery of experimental compounds in GBM orthotopic mouse models. Compounds delivered through this route can bypass the blood-brain barrier and thus help validate effective therapeutic targets for GBMs. For complete details on the use and execution of this protocol, please refer to Pinkham et al. (2019). Elsevier 2021-01-21 /pmc/articles/PMC7821034/ /pubmed/33532737 http://dx.doi.org/10.1016/j.xpro.2020.100290 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Protocol
Eyme, Katharina M.
Carvalho, Litia
Badr, Christian E.
Intranasal delivery of experimental compounds in orthotopic brain tumor mouse models
title Intranasal delivery of experimental compounds in orthotopic brain tumor mouse models
title_full Intranasal delivery of experimental compounds in orthotopic brain tumor mouse models
title_fullStr Intranasal delivery of experimental compounds in orthotopic brain tumor mouse models
title_full_unstemmed Intranasal delivery of experimental compounds in orthotopic brain tumor mouse models
title_short Intranasal delivery of experimental compounds in orthotopic brain tumor mouse models
title_sort intranasal delivery of experimental compounds in orthotopic brain tumor mouse models
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821034/
https://www.ncbi.nlm.nih.gov/pubmed/33532737
http://dx.doi.org/10.1016/j.xpro.2020.100290
work_keys_str_mv AT eymekatharinam intranasaldeliveryofexperimentalcompoundsinorthotopicbraintumormousemodels
AT carvalholitia intranasaldeliveryofexperimentalcompoundsinorthotopicbraintumormousemodels
AT badrchristiane intranasaldeliveryofexperimentalcompoundsinorthotopicbraintumormousemodels

Ejemplares similares